EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) announced today that co-founders Marc Hellerstein M.D., Ph.D., Chairman of the Scientific Advisory Board of KineMed and David Fineman, KineMed’s CEO, will present at the 2012 Personalized Medicine World Conference, on January 23rd at the Computer History Museum at 1401 North Shoreline Blvd, Menlo Park, CA.
Dr. Hellerstein’s presentation will take place at 11:00 AM, during the Emerging Technologies Session, and is titled, “Proteomics: Proteome Dynamics and Tissue Flux Imaging.”
Mr. Fineman’s presentation, “Pivotal Decisions in Healthcare Empowered by Dynamic Proteomics,” will take place at 1:00 PM in the Podium Presentation track.
“Using KineMed’s technologies, major pharmaceutical companies now have an unparalleled opportunity to navigate fundamental processes that cause complex disease. Our revolutionary ability to measure key points in disease pathways, and predict efficacy and toxicity, addresses our clients’ critical problem of pipeline attrition, saving them time, money and resources in developing better and more personalized medicines,” said Mr. Fineman.
About KineMed, Inc.
KineMed, Inc. (http://www.kinemed.com) based in California, is a world-leader in measuring dynamic biochemical processes that cause disease. Collaboration with KineMed offers deep expertise and access to technology to accelerate and lower the cost of drug R&D, as well as enabling new disease-modifying therapies, and the diagnosis and monitoring of patients. KineMed’s patented mass spectrometric technologies measure molecular fluxes in living tissues through the complex molecular and cellular networks that are responsible for disease.
KineMed’s field-leading technologies include Network Dynamics which offers the ability to measures changes in the dynamics of hundreds of proteins, to enable diagnosis and monitoring of cardiovascular, neurodegenerative, metabolic and other disorders from a drop of blood; and the Kinetic Microscope which displays spatial organization of metabolic fluxes in histopathologic specimens to provide functional signatures of disease in situ.
KineMed’s established programs with premier pharmaceutical collaborators address critical challenges facing drug discovery:
- Focus on causes rather than symptoms: Generating pivotal knowledge for developing blockbuster drugs, by targeting underlying biochemical causes
- Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context
- Reduce late-stage attrition: Early, decision-relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
- Powerful assays of disease state: Custom-developed assays create companion diagnostic tests for personalized medicine
KineMed is seeking broad collaborations with pharmaceutical, CRO, histopathology, diagnostics, medical instruments and biotechnology partners.
About the Personalized Medicine World Conference
The Personalized Medicine World Conference (PMWC) is the only fully integrated conference to examine the advances and challenges of Personalized Medicine through a practical lens. PMWC brings together the thought-leaders of business, government, healthcare-delivery, research and technology into one information-rich, two-day conference.
For more information about the Personalized Medicine World Conference, please visit: http://pmwc2012.com